ACE2 and COVID-19: Given the above premises, it is tempting to hypothesize that ApoE4 inhibits the protein expression of ACE2, resulting in ACE2 downregulation, which reverses its protective effect and may lead to unfavourable outcomes in patients with COVID-19.